1-4 of 4
Ralph Zinner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Adam J. Luginbuhl, Jennifer M. Johnson, Larry A. Harshyne, Alban J. Linnenbach, Sanket K. Shukla, Angela Alnemri, Gaurav Kumar, David M. Cognetti, Joseph M. Curry, Nikita Kotlov, Zoya Antysheva, Sandrine Degryse, Kyle Mannion, Michael K. Gibson, James Netterville, Brandee Brown, Rita Axelrod, Ralph Zinner, Madalina Tuluc, Stacey Gargano, Benjamin E. Leiby, Ayako Shimada, My G. Mahoney, Ubaldo Martinez-Outschoorn, Ulrich Rodeck, Young J. Kim, Andrew P. South, Athanassios Argiris
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 915–927.
https://doi.org/10.1158/1078-0432.CCR-21-1816
Published: 01 March 2022
View article titled, Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Open the PDF for Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

Razelle Kurzrock, Douglas W. Ball, Marianna L. Zahurak, Barry D. Nelkin, Vivek Subbiah, Shabina Ahmed, Ashley O'Connor, Enusha Karunsena, Rose M. Parkinson, Justin A. Bishop, Yoonji Ha, Rajni Sharma, Christopher D. Gocke, Ralph Zinner, Michelle A. Rudek, Steven I. Sherman, Nilofer S. Azad
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5475–5484.
https://doi.org/10.1158/1078-0432.CCR-18-1881
Published: 13 September 2019
View article titled, A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Open the PDF for A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

Vivek Subbiah, Christian Meyer, Ralph Zinner, Funda Meric-Bernstam, Marianna L. Zahurak, Ashley O'Connor, Jason Roszik, Kenna Shaw, Joseph A. Ludwig, Razelle Kurzrock, Nilofer A. Azad
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4027–4034.
https://doi.org/10.1158/1078-0432.CCR-17-0272
Published: 01 August 2017
View article titled, Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Open the PDF for Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma in another window
Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors

Vali Papadimitrakopoulou, Sofia Agelaki, Hai T. Tran, Merrill Kies, Robert Gagel, Ralph Zinner, Edward Kim, Gregory Ayers, John Wright, Fadlo Khuri
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4151–4159.
https://doi.org/10.1158/1078-0432.CCR-04-1659
Published: 01 June 2005
View article titled, Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors
Open the PDF for Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors in another window